Positive interim Alpha DaRT data from multiple clinical trials in pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other clinical trials announced
“Today is truly a momentous day for Alpha Tau,” noted Alpha Tau CEO Uzi Sofer. “With these fantastic clinical results observed across a number of difficult cancers, we are now able to demonstrate the broader Alpha Tau vision: Beyond our historical activities treating patients with localized and unresectable tumors, we are now expanding our focus on treating internal organ tumors of high unmet need, as well as tumors in metastatic patients, by harnessing the potential systemic immune benefits of Alpha DaRT. We are incredibly excited to pursue treatment of these cancers further across a number of future clinical trials, with increased attention to launching U.S. clinical trials investigating Alpha DaRT treatment of the pancreas, the brain, and in combination with checkpoint inhibitors. We aim to continue to generate incredible results and hope for these patients of high unmet need.”
Share:
More News
Pnina Fishman, CSO & Chairperson of Can-Fite BioPharma, commented: “We are pleased to offer this compassionate use program with Namodenoson for eligible patient in the US to address the unmet medical needs for pancreatic cancer. Initiating this program is another milestone achieved for Namodenoson, and concurrently to our ongoing Phase
“We are deeply disappointed by these results from our Phase 1 trial. Despite continuing to demonstrate differentiated safety as a more combinable ADC, updated efficacy data suggest that treatment with EO-3021 does not meet our bar for success and is insufficient to provide patients a competitive benefit-risk profile compared to
Søren Bregenholt, CEO of Alligator, commented: “The FDA’s recognition of HLX22/AC101’s potential with Orphan Drug Designation is a notable recognition. While Alligator’s is not directly involved in the development of HLX22/AC101, we continue to follow its progress as it potentially represents future income to Alligator.”
“At Servier, we are dedicated to transforming patient care in areas with significant unmet needs. Our partnership to develop BDTX-4933 is an important opportunity in targeted cancer therapies, as we believe we can serve more people by helping the right patients find the right treatment, at the right time,” said
